Analysts predict peak annual sales of around $2.5 billion for Dupixent, which the FDA approved in March last year for eczema – known ... because it is also an injection. Patients may opt to ...

Dupixent may become the first targeted treatment ... to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled ...

Studies show that there are few if any, additional side effects from the COVID-19 vaccine for people with eczema. In one ...

Sanofi’s Dupixent eczema injection is likely to get its EU approval very soon – and the company has shared new data reinforcing its potential in patients who don't responded to the commonly ...

Eczema can be managed with certain self-care ... or mycophenolate mofetil Biologic agents, such as dupilumab (Dupixent) or lebrikizumab-lbkz (Ebglyss), are reserved for people who have tried ...

The ADEPT trial met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial ...

BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y ...

However, several Wall Street analysts compared the results to Sanofi SNY/Regeneron’s REGN blockbuster immunology drug Dupixent, which is also considered the standard of care in AD indication.

A GlobalData analyst has already stated Lilly’s asset will capture market share from Dupixent in the US. Despite the rivalries lying in wait, Galderma is hopeful for its injection. The pharma ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...